Ifosfamide, epirubicin and granulocyte colony-stimulating factor: A regimen for successful mobilization of peripheral blood progenitor cells in patients with multiple myeloma

Hematological Oncology

Volumn 19, Issue 2, 2001, Pages 59-66

  Arland, M ^a   Leuner, S ^b   Lange, S ^a   Bartsch, R ^b   Kahl, C ^c   Florschutz A ^a,b   Franke, A ^a   Hoffkes H G ^c  

^a KLINIKUM FULDA   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c DESSAU MEDICAL CENTER   (Germany)

Author keywords

Engraftment; High dose chemotherapy; Multiple myeloma; Stem cells; Transplantation

Indexed keywords

EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; BONE MARROW PURGING; CHEMICALLY INDUCED DISORDER; METHODOLOGY; MIDDLE AGED; PHARMACOKINETICS; PROSPECTIVE STUDY; STANDARD; STEM CELL MOBILIZATION;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW PURGING; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IFOSFAMIDE; LEUKOPENIA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; THERAPEUTIC EQUIVALENCY;

EID: 0034743255     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.669     Document Type: Article

References (30)

1. Myeloma, macroglobulinemia, and heavy chain disease
2. Prognostic variables and clinical staging in multiple myeloma factors and survival in multiple myeloma
3. The treatment of multiple myeloma
4. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French registry on autologous transplantation in multiple myeloma
5. Comparison of hematological recovery times and supportive care requirements for autologous recovery phase peripheral blood cell transplants, autologous bone marrow transplants and allogenic bone marrow transplants
6. A randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone morrow transplantation in lymphoma patients
7. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts
8. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests
9. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF
10. Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF
11. Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)
12. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilisation in lymphoma, myeloma and solid tumours
13. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma
14. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: High-dose cyclophosphamide plus GM-CSF vs G-CSF alone
15. Where do we stand with respect to the use of peripheral blood progenitor cells?
16. Patient characteristics associated with successful mobilising and autografting of peripheral blood progenitor cells in malignant lymphoma
17. Peripheral blood stem cell transplants for multiple myeloma: Identification of favourable variables for rapid engraftment in 225 patients
18. Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone
19. G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma and lymphoma
20. CD34+ cells mobilised by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF
21. Leukapheresis products in multiple myeloma: Lower tumor load after mobilization with cyclophosphamide plus G-CSF compared to G-CSF in steady-state
22. GM-CSF for peripheral blood stem cell harvest in myeloma
23. Peripheral blood progenitor cell collections in multiple myeloma: Predictors and management of inadequate collections
24. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF
25. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF); an analysis of factors correlating with the tempo of engraftment after transplantation
26. Factors influencing collection and engraftment of autologous peripheral blood stem cells
27. Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with or without recombinant human granulocyte-macrophage colony-stimulating factor
28. 2 and G-CSF for pre-treated lymphoma patients: A matched pairs analysis of 78 patients
29. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization
30. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens